Induced from the MVP-in-GxP-markets panel at the KENX AI in GxP East 2026 conference (2026-09-16-1420-mvp-ai-gxp-markets-panel), 2026-09-16.
Two validations, one product
The panel’s consensus definition: the MVP is the customer’s intended use, and AI changes none of it. Vendors owe full functional testing of what they ship; sponsors validate the product in their own context of use, because a vendor cannot assess patient risk without it. The division of labor follows the division of knowledge.
What it means for building
Compliance controls belong in the product from inception, Tool-driven risk assessment beats debate because owners dilute their own ratings, and emerging MVP expectations: AI-native interactions, embedded change management with automated change-boundary logs, headless architectures, accessibility documentation, and a drift toward continuous validation. The takeaway for anyone shipping AI into pharma: you are not shipping a model, you are shipping the first draft of someone else’s intended use statement. That draft is why The intended use statement is the master control lever for GxP AI, and why The wording of an intended use statement sets the regulatory burden is a product decision, not a later regulatory rewrite.
Related
- Strategy Scaling and Product MOC
- The intended use statement is the master control lever for GxP AI
- Compliance controls belong in the product from inception
- Tool-driven risk assessment beats debate because owners dilute their own ratings
- The wording of an intended use statement sets the regulatory burden